Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1474P - Patient characteristics and treatment patterns in patients with metastatic pancreatic cancer by BRCA/ATM status in the PRIOR-2 study

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Maria Sierra

Citation

Annals of Oncology (2021) 32 (suppl_5): S1084-S1095. 10.1016/annonc/annonc709

Authors

M.I. Sierra1, G. Adeboyeje2, S. Joo3, A. Bartels1, M. Field1, A. Buikema4, S. Jhamb4

Author affiliations

  • 1 Commercial Analytics, Optum, 55344 - Eden Prairie/US
  • 2 Us Oncology Medical Affairs, Merck & Co., Inc, 07033 - Kenilworth/US
  • 3 Mrl, Center For Observational & Real-world Evidence (core), Oncology, Merck & Co., Inc, 19454 - North Wales/US
  • 4 Health Economics And Outcomes Research, Optum, 55344 - Eden Prairie/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1474P

Background

Emerging evidence suggests BRCA1/2 or ATM gene mutation status in metastatic pancreatic cancer (mPC) could predict clinical benefit from platinum-based chemotherapy and targeted therapies. We examined treatment patterns by BRCA 1/2/ATM mutation status in patients with mPC receiving routine care in the United States.

Methods

We identified patients, ≥18 years, with mPC (≥2 PC diagnoses within 90 days and ≥1 diagnosis or ≥2 note mentions of metastatic disease) in Optum’s de-identified electronic health record database (1/1/2011 – 6/30/2020; N=42.5M). Index date was first diagnosis/note mention of metastatic disease. Patients were observed for 12 months pre-index for baseline characteristics and followed for up to 36 months or until death.

Results

Among 546 mPC patients tested for BRCA/ATM, 182 (33.3%) had BRCA/ATM mutation (POS), 94 (17.2%) had BRCA/ATM (NEG), and 270 (49.5%) unknown status. Patients were 66% and 60% female with mean (SD) age 65.1 (11.0) and 63.3 (10.5) years for POS and NEG, respectively. 43% of POS patients had 2+ metastases, 56% had liver metastases and 73% had visceral metastases. Only 30% of NEG patients had 2+ metastases, 53% had liver metastases and 70% had visceral metastases. At 36-months post-index, use of platinum-based therapies and PARP inhibitors was 64% vs 74% and 14% vs 0% in POS and NEG patients, respectively (Table). Table: 1474P

Most common first-line regimens & targeted therapies

6 Month 12 Month 24 Month 36 Month
BRCA POS BRCA NEG BRCA POS BRCA NEG BRCA POS BRCA NEG BRCA POS BRCA NEG
Treated Patients 76 38 80 39 82 39 82 39
Gemcitabine + Paclitaxel in 1st line 31.6% 26.3% 30.0% 25.6% 30.5% 25.6% 30.5% 25.6%
Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin in 1st line 23.7% 50.0% 22.5% 48.7% 22.0% 48.7% 22.0% 48.7%
Platinum-based Chemotherapy in any line/setting 52.6.% 63.2% 60.0% 74.4% 63.4% 74.4% 64.6% 74.4%
PARP Inhibitor in any line/setting 6.6% 0.0% 10.0% 0.0% 12.2% 0.0% 14.6% 0.0%

Conclusions

While there are few differences in patient and treatment characteristics between patients by BRCA/ATM status, BRCA/ATM POS patients had a greater number of metastases and PARP inhibitor use. There is need for further research to understand the role of BRCA/ATM status on treatment choice and outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Merck & Co., Inc.

Funding

Merck & Co., Inc.

Disclosure

M.I. Sierra: Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Other, Optum was contracted by Merck to conduct this research.: Merck & Co., Inc. G. Adeboyeje: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc. S. Joo: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc. A. Bartels: Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Other, Optum was contracted by Merck to conduct this research.: Merck & Co., Inc. M. Field: Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Other, Optum was contracted by Merck to conduct this research.: Merck & Co., Inc; Financial Interests, Personal, Stocks/Shares: Optum. A. Buikema: Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Other, Optum was contracted by Merck to conduct this research.: Merck & Co., Inc; Financial Interests, Personal, Stocks/Shares: Optum. S. Jhamb: Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Other, Optum was contracted by Merck to conduct this research.: Merck & Co., Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.